Virtual Library

Start Your Search

V. Scotti



Author of

  • +

    P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P3.02-024 - Lobectomy versus Stereotactic Ablative Radiotherapy (SABR) for Stage I Non Small Cell Lung Cancer (NSCLC) in 182 Patients (ID 2781)

      09:30 - 09:30  |  Author(s): V. Scotti

      • Abstract
      • Slides

      Background:
      Data from prospective randomized clinical trials are lacking in the comparison between lobectomy (L) and SABRT in operable patients and ongoing trials have troubles in recruiting. In inoperable patients a local control of 64-95% in retrospective and 92-98% in prospective trial is reported when BED is over 100 Gy.

      Methods:
      From 2003 to 2013, 182 I-IIA NSCLC patients were treated at our Institution. Clinical characteristics are summarized in table I; cyto-histological prove of NSCLC was available in all surgical patients and in 61/88 (69%) SABRT patients. Spirometry was available in 120/182 (66%). Response was evaluated according to RECIST criteria after primary treatment. Toxicity was graduated according to CTCAE version 4 criteria.

      RT Surg Total p^
      n=88 (%) n=94 (%) n=182(%)
      Gender
      Male 70(79.5) 61(64.9) 131(72.0) 0.032
      Female 18(20.5) 33(35.1) 51(28.0)
      Age (median)
      <72 26(29.5) 67(71.3) 93(51.1) 0.0001
      >72 62(70.5) 27(28.7) 89(48.9)
      Hystology
      Adenocarcinoma 36(59.0) 69(73.4) 105(67.7) 0.14
      SCC 23(37.7) 24(25.5) 47(30.4)
      Large Cell Carcinoma 2(3.3) 1(1.1) 33(18.1)
      Performance Status
      0 13(14.8) 62(66.0) 75(41.2) 0.0001
      1 45(51.1) 29(30.9) 74(40.7)
      2 30(34.1) 3(3.1) 33(18.1)
      FEV1
      <1.5 35(43.8) 7(17.5) 42(35.0) 0.005
      >1.5 45(56.2) 33(82.5) 78(65.0)


      Results:
      Median follow-up time was 25 months (range: 6-110). Three local relapses (LR) were observed in L and 18 in SABRT group (p=0,0001). No difference in distant metastases was observed (19 in L vs 18 in SABRT group) (p=1-data not shown). Results of univariate survival analysis are shown in table II. Multivariate analysis confirmed the protective effect of L on OS and of good FEV1 (>1,5L) on DFS. A subgroup comparison of SABRT patients treated with BED>100Gy vs surgical patients showed no difference in local control (LC) (p=0,60) while OS and tumor-specific survival (TSS) remain in favor of L (p=0,001 and 0,049 respectively). Moreover, comparing surgical patients with SABRT with known histology and BED>100 Gy no difference was seen in TSS (p=0.10) nor in LC (p=0,36). No grade 3-5 toxicity was observed in both group.
      Died % OS p^ LR % DFS p^
      Age (median) <72 26 56.1 0.001 10 84.3 0.50
      >72 50 10 11 79.9
      Hystology Adenocarcinoma 34 37.9 0.66 9 87 0.81
      SCC 22 35 3 91.2
      Large Cell Carcinoma 1 66.7 0 100
      Performance Status 0 17 59.8 0.001 7 87.3 0.52
      1 29 19 9 79.5
      2 3 18.3 5 81
      FEV1 <1.5 27 20.4 0.14 11 86.2 0.005
      >1.5 37 14 7 80.9
      Treatment Radiotherapy 62 4.4 0.0001 18 67.4 0.0001
      Surgery 14 72.9 3 95.1
      Total 76 12.2 21 82.4


      Conclusion:
      SABRT with adequate doses vs L in operable patients shows promising results in terms of LC and TSS with few toxicitiy. OS is mainly influenced by the selection of patients addressed to L vs SABRT.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.